Antidepressant efficacy in the treatment of dysthymia

European Neuropsychopharmacology

Volumn 7, Issue SUPPL. 3, 1997, Pages

  Invernizzi, G ^a   Mauri, M C ^a   Waintraub, L ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM; MAPROTILINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; SULPIRIDE; TIANEPTINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

CONFERENCE PAPER; DEPRESSION; DYSTHYMIA; HUMAN; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DYSTHYMIC DISORDER; HUMANS;

EID: 0030723845     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00065-5     Document Type: Conference Paper

References (43)

1. Agnoli, A., Ravizza, L., Torta, R., 1989. Studio controllato in doppio cieco nelle sindromi distimiche (amisulpride versus amitriptilina). Atti, XXXVII Congresso SIP.
2. Akiskal H.S., Bitar A.H., Puzantian V.R., Rosenthal T.L., Walker P.W. The nosological status of neurotic depression: a prospective three-to four-year follow-up examination in light of the primarysecondary distinction and unipolar-bipolar dichotomies. Arch. Gen. Psychiatry. 35:1978;756-766.
3. Akiskal H.S. Dysthymic disorder, psychopathology of proposed chronic depressive subtypes. Am. J. Psychiatry. 140:1983;11-21.
4. Akiskal H.S. Dysthymia: clinical and external validity. Acta Psychiatr. Scand. 89(suppl 383):1994;19-23.
5. Bland R.C., Om H., Newman S.C. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr. Scand. 77:1988;24-32.
6. Boyer P., Lecrubier Y., Puech A. Treatment of dysthymia with low doses of amisulpride vs amineptine. Clin. Neuropharmacol. 15:1992;23.
7. Chodoff P. The depressive personality: a critical review. Arch. Gen. Psychiatry. 27:1972;666-673.
8. Cooper A.M., Michels R. Book review: American Psychiatric Association: Diagnostic and Statistical Manual of Mental disorders, 3rd-ed. Am. J. Psychiatry. 138:1981;128-129.
9. Costa e Silva J.A. Traitement des dhysthymies par de faibles doses d'amisulpride. Etude comparative amisulpride 50 mg versus placebo. Ann. Psychiatr. 5:1990;242-249.
10. De Jonghe F., Swinkels J.A. The safety of antidepressants. Drugs. 43(2):1992;40-47.
11. De Wilde J., Mertens C., Fredricson Overø K., Høpfner Petersen H.E. Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatr. Scand. 72(1):1985;89-96.
12. Fawcett, J., 1990. Targeting treatment in patients with mixed symptoms of anxiety and depression. J. Clin. Psychiatry 51(11) (suppl.), 40-43.
13. Frances A.J., Kocsis J., Marin D., Manning D., Markowitz J., Mason B., Widiger T. Implications of recent research on dysthymic disorders. Diagnostic criteria for dysthymic disorder. Psychopharmacol. Bull. 25:1989;325-329.
14. Goldberg H.L., Rickels K., Finnerty R. Treatment of neurotic depression with a new antidepressant. J. Clin. Psychopharmacol. 1(6S):1981;35-58.
15. Gonella G., Baignoli G., Ecari U. Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. Curr. Med. Res. Op. 12(3):1990;177-184.
16. Hellerstein D.J., Janowitch P., Rosenthal J., Samstag L.W., Maurer M.A.M., Kasch K., Buttews L., Poster M., Cantillon M., Winston A. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am. J. Psychiatry. 150:1993;1169-1175.
17. Hirschfeld, R.M.A., Holzer, C.E., 1994. Depressive personality disorder: clinical implications. J. Clin. Psychiatry 55(4) (suppl.), 10-17.
18. Howland R.H. Pharmacotherapy of dysthymia: a review. J. Clin. Psychopharmacol. 11(2):1991;83-92.
19. Howland R.H., Thase M.E. Biological studies of dysthymia. Biol. Psychiatry. 30:1991;283-304.
20. Invernizzi G., Aguglia E., Bertolino A., Casacchia M., Ciani N., Marchesi G.F., Nardini M., Rapisarda V. The efficacy and safety of tieneptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs amitriptyline. Neuropsychobiol. 12(2-3):1994;85-93.
21. Keller M.B., Lavori P.W. Double depression, major depression and dysthymia: distinct entities or different phases of a single disorder? Psychopharmacol. Bull. 20:1984;399-402.
22. Keller M.B., Klein D.N., Hirschfeld R.M.A., Kocsis J.H., McCullough J.P., Miller I., First M.B., Holzer C.P., Keitner G.I., Marin D.B., Shea T. Results of the DSM-IV mood disorders field trial. Am. J. Psychiatry. 152(6):1995;843-849.
23. Kendell R.E. The classification of depressions: a review of contemporary confusion. Br. J. Psychiatry. 129:1976;15-28.
24. Klein D.N., Taylor E.B., Dickstein S. The early-late onset distinction in DSM-III-R dysthymia. J. Affective Disord. 14:1988;25-33.
25. Klerman G.L., Endicott J., Spitzer R. Neurotic depressions: a systematic analysis of multiple criteria and multiple meanings. Am. J. Psychiatry. 136:1979;57-61.
26. Kocsis J.M., Frances A.J. A critical discussion of DSM-III dysthymic disorder. Am. J. Psychiatry. 144:1987;1534-1542.
27. Kovacs M., Feinberg T.L., Crense-Novak M., Paulauskas S.L., Finkelstein R. Depressive disorders in childhood, I: a longitudinal prospective study of characteristics and recovery. Arch. Gen. Psychiatry. 41:1984;229-237.
28. Kovacs M., Feinberg T.L., Crense-Novak M., Paulauskas S.L., Finkelstein R. Depressive disorders in childhood, II: a longitudinal study of the risk for a subsequent major depression. Arch. Gen. Psychiatry. 41:1984;643-649.
29. Kovacs M., Akiskal H.S., Gatsonis C., Parrone P.L. Childhood-onset dysthymic disorders: clinical features and prospective naturalistic outcome. Arch. Gen. Psychiatry. 51:1994;365-374.
30. Lapierre, Y.D., 1994. Pharmacological therapy of dysthymia. Acta Psychiatr. Scand. 89, 3835S, 42-48.
31. Lecrubier Y., Boyer P., Puech A.J., Aubin F., Rein W. Amisulpride versus imipramine and placebo in dysthymia. Clin. Neuropharmacol. 15(1S):1992;526.
32. Montgomery, S.A., 1990. Anxiety and depression. Wrightson Biomedical Publishing LTD, Petersfield.
33. Myers J.M., Weissman M.M., Tischler G.L. Six-month prevalence of psychiatric disorders in three communities,1980 to 1982. Arch. Gen. Psychiatry. 41:1984;959-967.
34. Paykel E.S., Hollyman J.A., Freeling P., Sedgwick P. Predictors of therapeutic benefits from amitriptyline in mild depression; a general practice placebo control trial. J. Affect. Disord. 14:1988;83-95.
35. Robins, E., Guze, S.B., 1972. Classification of affective disorders: the primary-secondary, the endogenous-reactive and the neurotic-psychotic concepts. In: Williams, T.A., Katz, M.M., Shields, J.A. (Eds.), Recent advances in the psychobiology of the depressive illness, Washington, DC, US Governement Printing Office.
36. Robins L.N., Helzer J.E., Weissman M.M. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry. 41:1984;949-958.
37. Scarzella R., Scarzella L., Rovera G.G. Amisulpride vs sulpiride, studio clinico in doppia cieco su 68 pazientiaffetti da disturbo distimico. Giornale Neuropsicofarm. 2:1988;73-78.
38. Smeraldi E., Haefele E., Crespi G., Casadei G.L., Biondi F., Vigorelli E. Amisulpride versus fluoxetine in dysthymia: preliminary results of a double-blind comparative study. Eur. Psychiatry. 11(3S):1996;33-35.
39. Spitzer R.L., Endicott J., Robins J.E. Research diagnostic criteria, rationale and reliability. Arch. Gen. Psychiatry. 35:1978;773-782.
40. Stollmaier W., Cimander K.P., Wagner W. Efficacy and tolerance of fluvoxamine in depressive syndromes in the practice. The results of a multicenter study on 2296 patients. Nervenheilkunde. 8:1989;247-252.
41. Weissman M.M., Klerman G.L. The chronic depressive in the community: under-recognized and poorly treated. Compr. Psychiatry. 18:1977;523-531.
42. Weissman M.M., Leaf P.J., Bruce M.L., Florio L. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am. J. Psychiatry. 145:1988;815-819.
43. WPA Dysthymia Working Group, 1995. Dysthymia in clinical practice. Br. J. Psychiatry 166, 174-183.